San Francisco-based Omada Health is looking to boost its workforce and widen its focus with a newly closed $23 million Series B round.
Funding was led by Andreessen Horowitz, which also contributed general partner Balaji Srinivasan to Omada’s board of directors. Other funding included Kaiser Permanente Ventures and existing investors U.S. Venture Partners and The Vertical Group, Omada announced.
The company boasts teammates from the likes of Google, Amazon, IDEO, Harvard and Stanford, calling its efforts a marriage of medicine and design. Omada’s flagship Prevent product is a digital diabetes prevention program that combines online elements such as coaching from health professionals, a support group of other participants and learning modules with sleek technologies such as a wireless digital scale, pedometer and other tools to help track, analyze and modify behavior.
The goal is to remedy an "unacceptable paradox" in modern society, CEO and co-founder Sean Duffy said in prepared remarks.
"Despite staggering technological advances in nearly every aspect of our lives, for the first time in history we find that preventable, chronic disease now kills more people than infectious disease," he said. "Omada’s mission is to inspire people to alter the habits that place them at risk for serious but preventable conditions."
Omada hopes to use the new funding to expand beyond diabetes to other chronic conditions and to double its workforce. The company hopes to have at least 1 program on the market by 2015, MobiHealthNews reported.